Methods and compositions for preserving the mucosal barrier
US-2015297619-A1 · Oct 22, 2015 · US
Administration of serine protease inhibitors to the stomach
US9504736B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9504736-B2 |
| Application number | US-201113825779-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 23, 2011 |
| Priority date | Sep 23, 2010 |
| Publication date | Nov 29, 2016 |
| Grant date | Nov 29, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum.
First claim
Opening claim text (preview).
What is claimed is: 1. An aqueous pharmaceutical formulation comprising a therapeutically effective amount of 0.16 wt % to 1.80 wt % of tranexamic acid, polyethylene glycol-3350, and electrolytes; wherein the formulation has a volume of 500 ml to 1000 ml. 2. The formulation of claim 1 , wherein the formulation is a single dose formulation.
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
Drugs for disorders of the alimentary tract or the digestive system · CPC title
Drugs for disorders of the nervous system · CPC title
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327) · CPC title
having an amino or nitro group · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9504736B2 cover?
- The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube u…
- Who is the assignee on this patent?
- Schmid-Schonbein Geert W, Lee Yung-Tsai (Andrew), Wei Jeng, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/57. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).